Columbia Partners L L C Investment Management increased its position in Pfizer, Inc. (NYSE:PFE) by 11.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 50,813 shares of the biopharmaceutical company’s stock after buying an additional 5,316 shares during the period. Columbia Partners L L C Investment Management’s holdings in Pfizer were worth $1,738,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of the company. Norges Bank bought a new stake in Pfizer during the fourth quarter worth $1,896,890,000. Fisher Asset Management LLC raised its stake in shares of Pfizer by 1.7% in the first quarter. Fisher Asset Management LLC now owns 32,759,530 shares of the biopharmaceutical company’s stock valued at $1,120,704,000 after buying an additional 554,777 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of Pfizer by 1.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 31,260,823 shares of the biopharmaceutical company’s stock valued at $1,069,433,000 after buying an additional 377,404 shares in the last quarter. Macquarie Group Ltd. raised its stake in shares of Pfizer by 0.9% in the first quarter. Macquarie Group Ltd. now owns 24,683,746 shares of the biopharmaceutical company’s stock valued at $844,431,000 after buying an additional 228,405 shares in the last quarter. Finally, Boston Partners raised its stake in shares of Pfizer by 7.3% in the first quarter. Boston Partners now owns 24,263,989 shares of the biopharmaceutical company’s stock valued at $830,071,000 after buying an additional 1,649,801 shares in the last quarter. Institutional investors own 69.94% of the company’s stock.
Shares of Pfizer, Inc. (PFE) traded down 0.85% during midday trading on Friday, reaching $32.67. The company’s stock had a trading volume of 15,490,145 shares. The stock has a market capitalization of $194.30 billion, a price-to-earnings ratio of 23.90 and a beta of 1.00. Pfizer, Inc. has a 52 week low of $29.83 and a 52 week high of $35.38. The company has a 50 day moving average of $33.30 and a 200-day moving average of $33.38.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The business had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same period in the prior year, the company earned $0.64 earnings per share. The business’s revenue was down 1.9% compared to the same quarter last year. Equities research analysts predict that Pfizer, Inc. will post $2.56 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Friday, August 4th will be issued a $0.32 dividend. The ex-dividend date is Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.92%. Pfizer’s payout ratio is 94.12%.
TRADEMARK VIOLATION NOTICE: “Columbia Partners L L C Investment Management Has $1.74 Million Stake in Pfizer, Inc. (PFE)” was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://stocknewstimes.com/2017/08/20/columbia-partners-l-l-c-investment-management-has-1-74-million-stake-in-pfizer-inc-pfe.html.
Several brokerages have recently commented on PFE. BidaskClub upgraded Pfizer from a “strong sell” rating to a “sell” rating in a report on Friday, June 23rd. BMO Capital Markets reiterated a “hold” rating and set a $33.00 price objective on shares of Pfizer in a report on Thursday, April 27th. Sanford C. Bernstein reiterated a “buy” rating and set a $35.00 price objective on shares of Pfizer in a report on Monday, April 24th. Credit Suisse Group lowered Pfizer from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $38.00 to $36.00 in a report on Thursday, July 20th. Finally, Barclays PLC reiterated a “buy” rating and set a $38.00 price objective on shares of Pfizer in a report on Wednesday, May 3rd. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $37.61.
In other news, CEO Ian C. Read sold 96,950 shares of the company’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $34.00, for a total value of $3,296,300.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $33.50, for a total transaction of $502,500.00. Following the completion of the sale, the insider now directly owns 151,474 shares of the company’s stock, valued at $5,074,379. The disclosure for this sale can be found here. 0.06% of the stock is currently owned by corporate insiders.
About Pfizer
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
